Immuron Announces Travelan Clinical Trial Update
Filed with ASX · · 4 pages · English
Summary by 6ix AI
The trial demonstrated statistically significant reductions in antibody levels and improved microbiome stability in participants receiving Travelan compared to those on placebo. This update reflects Immuron's ongoing commitment to developing Travelan as a treatment for travelers' diarrhea caused by pathogenic bacteria.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Immuron
- NMRC Reports Results for Campylobacter Clinical Study
- Trading Halt
- Immuron Plans Phase 2 Trial for IMM-529 following FDA review
- Appendix 4E and Preliminary Final Report
- Immuron Travelan record sales globally, Australia and USA
Later from Immuron
- Immuron Travelan continued strong sales growth
- IMC and Calmino to treat Irritable Bowel Syndrome (IBS)
- Immuron and Calmino join up to treat Irritable Bowel Syndrome (IBS)
- Immuron Travelan highest sales in history
- FY25 global sales exceed projection, up 49% on prior year
Follow Immuron into a list and get an email when it puts out news.
Follow Immuron